ValiRx (LSE:VAL) Price-to-Tangible-Book : 1.94 (As of May. 08, 2024)

View and export this data going back to 2000. Start your Free Trial

What is ValiRx Price-to-Tangible-Book?

As of today (2024-05-08), ValiRx's share price is £0.033. ValiRx's Tangible Book per Share of Jun. 2023 for the quarter that ended in Jun. 2023 was £0.02. Hence, ValiRx's Price to Tangible Book Ratio of today is 1.94.

The historical rank and industry rank for ValiRx's Price-to-Tangible-Book or its related term are showing as below:

LSE:VAL' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.63 Med: 8.93 Max: 61.45
Current: 1.65

During the past 13 years, ValiRx's highest Price to Tangible Book Ratio was 61.45. The lowest was 1.63. And the median was 8.93.

LSE:VAL's Price-to-Tangible-Book is ranked better than
70.38% of 1222 companies
in the Biotechnology industry
Industry Median: 2.77 vs LSE:VAL: 1.65

A closely related ratio is called PB Ratio. As of today, ValiRx's share price is £0.033. ValiRx's Book Value per Sharefor the quarter that ended in Jun. 2023 was £0.04. Hence, ValiRx's P/B Ratio of today is 0.80.

ValiRx Price-to-Tangible-Book Historical Data

The historical data trend for ValiRx's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx Price-to-Tangible-Book Chart

ValiRx Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Price-to-Tangible-Book

Get a 7-Day Free Trial

6.29

25.89

8.24

ValiRx Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Price-to-Tangible-Book	Get a 7-Day Free Trial															8.93	25.89	35.83	8.24	4.26

Competitive Comparison of ValiRx's Price-to-Tangible-Book

For the Biotechnology subindustry, ValiRx's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ValiRx's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ValiRx's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where ValiRx's Price-to-Tangible-Book falls into.

ValiRx Price-to-Tangible-Book Calculation

ValiRx's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Jun. 2023 )
	=	0.033	/	0.017
	=	1.94

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

ValiRx Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of ValiRx's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

ValiRx (LSE:VAL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

EAJF:Germany

Address

4 Barling Way, Eliot Park Innovation Centre, Nuneaton, GBR, CV10 7RH

Website

https://www.valirx.com

ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, NAV3 for the cancer screening test, and VAL401 for lung cancer.